Metoprolol 25 mg - Bisoprolol Equivalent

The math

Important caveats

1. Formulation matters - The conversion above applies to metoprolol succinate (SR/XL, once daily). If you are using metoprolol tartrate (IR, given twice daily), then 25 mg twice daily (total 50 mg/day) would equate to bisoprolol ~2.5 mg once daily.
2. No definitive conversion exists - As NHS Scotland explicitly states, "there is no definitive guidance for dose conversion between beta-blockers." These tables are rough guides based on usual dose ranges.
3. Indication-specific titration - For heart failure, bisoprolol starting dose is 1.25 mg/day (regardless of what the patient was on), titrated upward. For hypertension or angina, target doses differ.
4. Clinical monitoring is required after any switch - check heart rate, blood pressure, and symptom response to guide the final dose.

Switching from Metoprolol to Bisoprolol: Safe Transition Protocol

Why the switch is generally safe

Step-by-Step Protocol

• Stop the last metoprolol dose the night before (or 12 hours prior)
• Begin bisoprolol the next morning at the equivalent dose or one step lower if there is any concern about tolerability (e.g. baseline HR < 65, elderly, borderline hypotension)
• Do not abruptly discontinue metoprolol without immediately starting bisoprolol - this risks rebound tachycardia, especially in ischaemic heart disease

• Check HR and BP within 24-48 hours of the switch
• Target resting HR: 55-65 bpm (heart failure) or 60-70 bpm (hypertension/angina)
• Hold or reduce bisoprolol if HR < 50 bpm or systolic BP < 90 mmHg

• Assess HR, BP, symptoms (fatigue, dizziness, dyspnoea)
• Titrate bisoprolol upward every 2-4 weeks if target dose not yet reached

Indication-Specific Notes

• A 2007 study of 282 HF patients used exactly this protocol - metoprolol tartrate stopped 12 hours before bisoprolol initiation. It was safe and effective; mean HR dropped from 84 to 67 bpm. Only 28.5% reached the 10 mg target, so individual titration is essential.
• Note: in de novo HF patients (not switching), bisoprolol is started at 1.25 mg and titrated up. For a switch, you can start at the equivalent dose since the patient is already beta-blocked.

• Direct same-day switch is well tolerated. Use equivalent dose per the table above.
• NHS Scotland guidance confirms there is no definitive conversion but emphasises clinical monitoring over rigid dose matching.

• Extra caution warranted. Consider starting bisoprolol at a slightly lower equivalent dose and titrating up over 2-4 weeks.

Red Flags - When to Slow Down or Avoid the Switch

• Resting HR < 55 bpm before the switch
• Systolic BP < 100 mmHg
• Decompensated heart failure (active fluid overload)
• Recent ACS within the past 2 weeks
• Concurrent rate-limiting drugs: diltiazem, verapamil, amiodarone, digoxin (additive bradycardia risk)
• Sick sinus syndrome or high-degree AV block without pacemaker

Key Practical Points

1. Bisoprolol is once-daily only - make sure the patient understands this vs. twice-daily metoprolol tartrate
2. Bisoprolol has longer half-life (~10-12 hours vs. metoprolol IR ~3-7 hours) - more stable trough levels, which is part of why the switch is often beneficial
3. Bisoprolol is more cardioselective than metoprolol at equivalent doses - better choice for patients with mild COPD or asthma
4. Do not crush or chew either extended-release formulation
5. Document the reason for switching and the dose chosen in the patient record

Beta-Blockers + Calcium Channel Blockers (CCBs): The Critical Distinction

Class 1: Dihydropyridines (DHP-CCBs) - SAFE to combine ✅

• Additive BP reduction
• Better heart rate control
• Complementary mechanism - beta-blocker counters the reflex tachycardia that nifedipine can cause
• This is a recommended combination for hypertension and angina

Class 2: Non-Dihydropyridines (Non-DHP CCBs) - GENERALLY AVOID ⚠️

• Severe bradycardia
• High-degree AV block (2nd or 3rd degree)
• Potentially fatal bradyarrhythmias
• Cardiac arrest in overdose

Summary Table

Special Situations

• Sometimes diltiazem + beta-blocker is used short-term in AF when rate is hard to control, but this must be done with very close monitoring, at low doses, and ideally in a monitored setting.
• Verapamil + beta-blocker remains essentially contraindicated even in AF.

• Beta-blocker + long-acting amlodipine or nifedipine is a standard second-line combination with good evidence.

• CCB + beta-blocker overdose is one of the most lethal drug poisoning scenarios in emergency medicine (Rosen's EM). Treatment requires high-dose insulin-glucose therapy, lipid emulsion, and potentially ECMO.

Monitoring when combining (DHP-CCBs only)

• HR (target 55-65 in angina/HF, 60-70 in HTN)
• BP (watch for additive hypotension)
• Symptoms: dizziness, fatigue, peripheral oedema (amlodipine-related)
• ECG if any bradycardia or conduction concern

Diltiazem 90 mg SR + Metoprolol Succinate: What You Need to Know

Why This Combination Is Risky

When Is This Combination Clinically Used?

• When a single agent fails to achieve adequate rate control
• Usually short-term or in a monitored setting
• Diltiazem SR 90 mg + metoprolol succinate 25-50 mg is a recognised combination in AF rate control

• When beta-blocker alone is insufficient
• Diltiazem adds coronary vasodilation + further rate reduction

• Dual rate control + BP benefit

Absolute Contraindications for This Combination

• Pre-existing 2nd or 3rd degree AV block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Resting HR < 55 bpm
• Systolic BP < 90 mmHg
• Decompensated heart failure / low EF (both are negatively inotropic)
• WPW syndrome with AF (both block the AV node, can accelerate accessory pathway conduction)

Safe Use Protocol (When Clinically Justified)

• Use the lowest effective dose of each - diltiazem SR 90 mg once daily is already a moderate dose
• Metoprolol succinate: start at 25 mg and go no higher than needed
• Do NOT add diltiazem to a patient already on high-dose metoprolol (≥100 mg) without ECG review first

• Check HR + BP at 48-72 hours after initiating the combination
• Repeat ECG at 1-2 weeks
• Educate patient: report palpitations, near-fainting, unusual fatigue, or swollen ankles immediately

Practical Bottom Line

Bisoprolol vs Metoprolol When Combined With Diltiazem

The Core Issue: Different Metabolic Pathways

• Diltiazem inhibits CYP3A4, which metabolises bisoprolol. This means bisoprolol blood levels are higher and less predictable when co-prescribed with diltiazem.
• Metoprolol uses CYP2D6, which diltiazem does not inhibit - so metoprolol levels are not significantly raised by diltiazem pharmacokinetically.

So Which Is Safer With Diltiazem?

Pharmacokinetic safety (drug level interaction) - Metoprolol wins

• No CYP3A4 interaction with diltiazem
• More predictable plasma levels
• Dose you give is closer to the dose effect you get

Pharmacodynamic safety (heart rate/conduction effect) - Both carry equal risk

• Both bisoprolol AND metoprolol slow the SA node and AV node
• Both will have additive bradycardic and AV-blocking effects with diltiazem
• Neither is "safer" in terms of conduction risk

Overall additive risk summary

Practical Clinical Recommendation

Bottom Line

When diltiazem is on board, metoprolol is the pharmacokinetically cleaner choice because it bypasses the CYP3A4 pathway that diltiazem inhibits. Bisoprolol's elevated levels via CYP3A4 inhibition add an unpredictable layer on top of the already significant pharmacodynamic interaction both drugs share with diltiazem. In either case - start at the lowest dose, check ECG + HR within 48-72 hours, and avoid this combination entirely in patients with pre-existing bradycardia, AV block, or impaired LV function.